Business Description
MaxCyte Inc
NAICS : 334510
SIC : 3845
ISIN : US57777K1060
Description
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.4 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 7.04 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.1 | |||||
| 3-Year EBITDA Growth Rate | -47.2 | |||||
| 3-Year EPS without NRI Growth Rate | -32.3 | |||||
| 3-Year FCF Growth Rate | -18.7 | |||||
| 3-Year Book Growth Rate | 60 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.38 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.88 | |||||
| 9-Day RSI | 54.12 | |||||
| 14-Day RSI | 56.63 | |||||
| 6-1 Month Momentum % | -16.4 | |||||
| 12-1 Month Momentum % | -22.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.81 | |||||
| Quick Ratio | 9.22 | |||||
| Cash Ratio | 8.73 | |||||
| Days Inventory | 672.74 | |||||
| Days Sales Outstanding | 46.92 | |||||
| Days Payable | 64.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.9 | |||||
| Shareholder Yield % | -0.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.06 | |||||
| Operating Margin % | -101.17 | |||||
| Net Margin % | -77.86 | |||||
| FCF Margin % | -46.56 | |||||
| ROE % | -15.69 | |||||
| ROA % | -13.67 | |||||
| ROIC % | -55.13 | |||||
| ROC (Joel Greenblatt) % | -116.24 | |||||
| ROCE % | -18.89 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.56 | |||||
| PB Ratio | 2.14 | |||||
| Price-to-Tangible-Book | 2.14 | |||||
| EV-to-EBIT | -6.56 | |||||
| EV-to-EBITDA | -7.24 | |||||
| EV-to-Forward-EBITDA | -10.6 | |||||
| EV-to-Revenue | 6.64 | |||||
| EV-to-Forward-Revenue | 5.6 | |||||
| EV-to-FCF | -14.31 | |||||
| Price-to-Projected-FCF | 23.63 | |||||
| Price-to-Net-Current-Asset-Value | 3.32 | |||||
| Price-to-Net-Cash | 3.86 | |||||
| Earnings Yield (Greenblatt) % | -15.24 | |||||
| FCF Yield % | -4.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MaxCyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 41.845 | ||
| EPS (TTM) (€) | -0.312 | ||
| Beta | 1.85 | ||
| Volatility % | 43.19 | ||
| 14-Day RSI | 56.63 | ||
| 14-Day ATR (€) | 0.148689 | ||
| 20-Day SMA (€) | 3.652 | ||
| 12-1 Month Momentum % | -22.17 | ||
| 52-Week Range (€) | 2.98 - 4.96 | ||
| Shares Outstanding (Mil) | 105.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MaxCyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MaxCyte Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
MaxCyte Inc Frequently Asked Questions
What is MaxCyte Inc(FRA:MYE0)'s stock price today?
The current price of FRA:MYE0 is €3.78. The 52 week high of FRA:MYE0 is €4.96 and 52 week low is €2.98.
When is next earnings date of MaxCyte Inc(FRA:MYE0)?
The next earnings date of MaxCyte Inc(FRA:MYE0) is 2025-03-12 Est..
Does MaxCyte Inc(FRA:MYE0) pay dividends? If so, how much?
MaxCyte Inc(FRA:MYE0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers